ZEVRA THERAPEUTICS, INC. business relationships
Companies named in ZEVRA THERAPEUTICS, INC.’s 10-K filed 2026-03-09, and public companies whose annual reports name ZEVRA THERAPEUTICS, INC.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.7 / 10
- AI naming
- 5 / 100 Top 3% in its category
- Agent readiness
- 60 / 100
- AI adoption
- 0 / 100
Named in ZEVRA THERAPEUTICS, INC.’s annual report 3
“We have exclusively licensed from Assistance Publique-Hôpitaux de Paris (AP-HP) a now-issued U.S. patent (US 11,523,997) titled "Method of Providing Celiprolol Therapy to a Patient," with an expiration date in November 2038, excluding any potential patent term extension, which covers certain methods...” SEC filing
“In connection with the AZSTARYS License Agreement, the Company pays Aquestive Therapeutics, Inc. ("Aquestive") a royalty equal to 10 % of all regulatory milestone and royalty payments.” SEC filing
“Corium Inc. was tasked by Commave to lead all commercialization activities for AZSTARYS under the AZSTARYS License Agreement.” SEC filing
Links are read automatically from public company filings, so every link carries the sentence it came from.
Not investment advice. Scores, rankings and connections are automated estimates from public sources, provided as is. Connections are read automatically from public company filings and may be incomplete or wrong. To correct or remove a company page or a connection, email [email protected]. Company names and logos belong to their owners. Showing them does not mean the company endorses Engagemii or that Engagemii endorses it. Terms